Failed Illumina and Sanofi Deals Shine Light on FTC Antitrust Crackdown

The news earlier this week that Illumina is divesting GRAIL marked the beginning of the end for a yearslong battle over cancer testing development—and another demonstration of the Federal Trade Commission’s increased scrutiny around potential antitrust violations. Just last week, another FTC challenge made headlines when Sanofi dropped a planned licensing agreement with California-based Maze Therapeutics to develop treatments for Pompe.